A device that will dramatically improve the protection of babies during birth. It will monitor the child continuously with better acuity, resulting in better clinical outcomes at a lower cost.

Projektinformationen

RepHorm

ID Finanzhilfevereinbarung: 652292

DOI 10.3030/652292

Abgeschlossenes Projekt

EK-Unterschriftsdatum 29 September 2014

Startdatum 1 Oktober 2014

Enddatum 28 Februar 2015

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

BLUEBRIDGE TECHNOLOGIES LIMITED
Ireland

Ziel

The objective of this Phase 1 application is a feasibility study to assess the commercial viability of RepHorM, and quantify the business opportunity.
This project is to develop a real-time in vivo infant monitor that safe guards the baby during birth. This achieved with a fiber optic based biomarker sensor. This device will for the first time provide doctors with a real-time, continuous and objective measure of a baby’s health during labour by incorporating this technology into an existing medical device. The learning curve will be small in taking up the new device and the specific biomarker, is very familiar to obstetricians as well as other clinicians, and the threshold levels for intervention are already established.
This Innovative solution uses latest technology deployed to an old, long standing problem. The research into the sensor chemistry has been now completed and this activity has moved the technology form TRL 3 to the current TRL 6. The worldwide market for monitoring was €6.2 Billion in 2010 and is predicted to increase by 4.4% compound annual growth rate (CAGR) to reach € 8 Billion in 2016. None of the current methods offer clear advantages over one another. The general trend in medicine is towards individual bedside or in-patient testing of key biomarkers, in particular, there is a trend towards continuous bio-diagnostics.
BlueBridge Technologies hope to use Phase 1 to identify obstacles to successful product development and launch, and develop solutions to manage them. The work will then serve to better understand and describe exactly what type of product(s) the market requires and subsequently estimate the development costs, time to Market and provide the inputs needed for a Phase 2 application.

Babies and the market need this product as they are currently under served by the current offerings and we passionately want to lead the response to this noble call.

Wissenschaftliches Gebiet

• engineering and technology › materials engineering › fibers
• engineering and technology › electrical engineering, electronic engineering, information engineering › electronic engineering › sensors
• natural sciences › physical sciences › optics › fibre optics

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

BLUEBRIDGE TECHNOLOGIES LIMITED

• Netto-EU-Beitrag: € 50 000,00
• Adresse: TALENT GARDEN DGU ALPHA OLD FINGLAS ROAD ; D11YNR2 DUBLIN ; Irland
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Ireland › Eastern and Midland › Dublin
• Region: Ireland › Eastern and Midland › Dublin
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00